Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

@article{Sznol2008PhaseIS,
  title={Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)},
  author={M. Sznol and F. S. Hodi and K. Margolin and D. McDermott and M. Ernstoff and J. Kirkwood and C. Wojtaszek and D. Feltquate and T. Logan},
  journal={Journal of Clinical Oncology},
  year={2008},
  volume={26},
  pages={3007-3007}
}
  • M. Sznol, F. S. Hodi, +6 authors T. Logan
  • Published 2008
  • Medicine
  • Journal of Clinical Oncology
  • 3007 Background: CD137 is a member of the TNFR family and functions as a costimulatory molecule. In preclinical studies BMS- 663513, a fully human anti-CD137 agonist monoclonal antibody provided costimulation to CD8+ and CD4+ T-cells, leading to enhanced IFNγ production, cytolytic activity, and increased survival. We conducted a first-in-human phase I dose-escalation study of BMS-663513 in pts with CA. Methods: BMS-663513 was administered IV every 3 weeks. In Part 1, the dose was escalated (0.3… CONTINUE READING
    175 Citations

    Topics from this paper

    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    • 63
    • PDF
    Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
    • 75
    • Highly Influenced
    Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
    • 86
    Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
    • 20
    • PDF
    Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies
    • 18
    Immunotherapy of Cancer with 4-1BB
    • 138
    • PDF
    Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
    • 144
    • PDF
    OX40 is a potent immune-stimulating target in late-stage cancer patients.
    • 332
    • PDF